SHARPE
Reported results
- Cash, cash equivalents and marketable securities of $266.3 million as of July 31, 2026
- Total operating expenses of $34.0 million for Q3 2026 compared to $29.9 million for Q3 2025
- Net loss attributable to common shareholders of $32.5 million ($0.47 per share, basic and diluted) for Q3 2026 compared to $29.0 million ($0.57 per share) for Q3 2025
- Research and development expenses of $20.1 million for Q3 2026 compared to $22.6 million for Q3 2025
- General and administrative expenses of $13.9 million for Q3 2026 compared to $7.4 million for Q3 2025
- Previously reported interim 54% complete response rate at any time and 3.2% progression to muscle-invasive disease in LEGEND’s pivotal Cohort 1
Guidance
- Data update on complete response at any time and maturing durability from LEGEND’s pivotal cohort planned for 4Q 2026
- Pre-BLA meeting with FDA on track for 4Q 2026
- Initiation of BLA submission for detalimogene planned for 4Q 2026
- Potential FDA approval decision for detalimogene and platform designation in 2027
Notes
Nine-month results also provided: nine-month net loss of $92.5 million ($1.34 per share) versus $79.4 million ($1.56 per share) for nine months ended July 31, 2025. Balance sheet shows total assets of $288.3 million and total shareholders’ equity of $230.3 million as of July 31, 2026.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-09-08 (8-K, Item 2.02). Read the original filing on sec.gov.